Showing 39,881 - 39,900 results of 63,199 for search '(( 01 ((1 decrease) OR (a decrease)) ) OR ( 50 ((nn decrease) OR (mean decrease)) ))', query time: 0.96s Refine Results
  1. 39881
  2. 39882

    Quantified data from alizarin red S staining depicting calcium deposition of UMR-106 cells under iron overload with (A) FAC and (B) FAS. by Kornkamon Lertsuwan (8911355)

    Published 2020
    “…<p>Both FAC and FAS significantly decreased osteoblast calcium deposition. **<i>P</i> < 0.01, ***<i>P</i> < 0.001 as compared to control group (0 μM).…”
  3. 39883
  4. 39884
  5. 39885

    How replay can hurt. by Georgy Antonov (11938961)

    Published 2022
    “…(F) Overall, we found that this MI subject, as predicted by our agent, mostly hurt himself by replaying at the end of each trial (average change in objective value function was decreased by 0.075 reward points, 1-sample 2-tailed t test, <i>t</i> = −3.26, <i>p</i> = 0.001). ** <i>p</i> < 0.01.…”
  6. 39886
  7. 39887
  8. 39888
  9. 39889

    Image2_The effect of tacrolimus conversion from immediate- to extended-release formulation on renal function in renal transplant patients: a meta-analysis.TIF by Sheng Chao (14799646)

    Published 2023
    “…Furthermore, in patients with a follow-up duration ≥48 weeks, Scr was decreased after conversion versus before conversion (p = 0.005), but eGFR remained unchanged (p = 0.68). …”
  10. 39890
  11. 39891
  12. 39892

    Top 50 results of a commercial kinase screen using [γ<sup>33</sup>]-ATP and human obscurin SH3-DH as substrates. by Daniel Koch (388049)

    Published 2023
    “…While MST2 addition resulted in strong and saturable phosphorylation, TBK1 led to much lower phosphorylation levels and CaMK4 addition led to an intermediate phosphorylation level exhibiting a biphasic behaviour with phosphorylation levels decreasing at higher substrate concentrations. …”
  13. 39893
  14. 39894

    Data_Sheet_1_Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis.PDF by Xiehui Chen (9538275)

    Published 2022
    “…In comparison to the control group, the data demonstrated that SGLT-2i is related with a decreased incidence of composite outcome (HR: 0.77, 95% CIs: 0.73–0.81, I<sup>2</sup> = 0%, P < 0.01), CV death (HR: 0.87, 95% CIs: 0.81–0.94, I<sup>2</sup> = 3%, P < 0.01), all-cause mortality (HR: 0.90, 95% CIs: 0.84–0.96, I<sup>2</sup> = 10%, P < 0.01), and hospitalization due to HF (HHF) (HR: 0.70, 95% CIs: 0.66–0.75, I<sup>2</sup> = 0%, P < 0.01). …”
  15. 39895
  16. 39896
  17. 39897
  18. 39898
  19. 39899
  20. 39900

    Table1_Left ventricular structure and function following renal sympathetic denervation in patients with HFpEF: an echocardiographic 9-year long-term follow-up.docx by Alexander Vogt (375813)

    Published 2024
    “…This decrease was due to a greater reduction in morphological and biomarker subcategories [from 1.95 ± 0.22 to 1.43 ± 0.51 points (P < 0.01) and from 1.52 ± 0.52 to 0.90 ± 0.63 points (P < 0.01), respectively] than in the functional one. …”